Although the program is primarily designed for CMOs, large pharma CMOs and other R&D decision-makers also attended to exchange best practices in drug development and business management.
We are pleased to welcome Dr Julie Krop, CMO, EVP, Clinical Development and Regulatory Affairs, AMAG Pharmaceuticals, Dr Zain Kassam, Co-Founder, EVP, Clinical Development and Translational Medicine, Finch Therapeutics and Dr Beth Garner, CMO, ObsEva as co-chairs for the 2021 CMO Summit.
This conference is dedicated to accomplishing two goals:
1) To bring together CMO and R&D executives to address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital and strategizing for appropriate exits.
2) To create a network of CMOs and R&D Leadership from small to mid-size life science companies to share ideas, solutions and support.
Key Topic Areas for 2021:
The Impact of Innovation on Drug Development Operations
The Realities of Transitioning from Brick-and-Mortar Trial Sites to DCTs
Effective Outsourcing that Truly Supports Development Goals
Building a Long-Term and Global Regulatory Strategy
Structuring and Managing a Team Post-COVID
Creative Hiring Strategies with Remote Working and a Tight Job Market
CMO Preparation for Investor Interactions
The First 90 Days in a CMO Role
In-Person Fee - USD 1495.0
Virtual Fee - USD 500.0
Aloft Boston Seaport District
401-403 D Street